Ciantra Z, Paraskevopoulou V, Aifantis I
Nat Immunol. 2025; 26(3):351-365.
PMID: 40021898
DOI: 10.1038/s41590-025-02096-9.
Filipek-Gorzala J, Kwiecinska P, Szade A, Szade K
Front Oncol. 2024; 14:1308709.
PMID: 38440231
PMC: 10910019.
DOI: 10.3389/fonc.2024.1308709.
Jiang Y, Zhao Y, Yu X, Yin L
Chin J Integr Med. 2023; 30(7):588-599.
PMID: 38085388
DOI: 10.1007/s11655-023-3561-z.
Aktar A, Heit B
J Mol Med (Berl). 2023; 101(10):1191-1208.
PMID: 37624387
DOI: 10.1007/s00109-023-02359-8.
Wen C, Lu X, Sun Y, Li Q, Liao J, Li L
Heliyon. 2023; 9(5):e15826.
PMID: 37206002
PMC: 10189189.
DOI: 10.1016/j.heliyon.2023.e15826.
Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review.
Teixeira A, Carreira L, Abalde-Cela S, Sampaio-Marques B, Areias A, Ludovico P
Cancers (Basel). 2023; 15(5).
PMID: 36900154
PMC: 10000116.
DOI: 10.3390/cancers15051362.
Properties of Leukemic Stem Cells in Regulating Drug Resistance in Acute and Chronic Myeloid Leukemias.
Zhai X, Jiang X
Biomedicines. 2022; 10(8).
PMID: 36009388
PMC: 9405586.
DOI: 10.3390/biomedicines10081841.
The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation.
Yeaton A, Cayanan G, Loghavi S, Dolgalev I, Leddin E, Loo C
Cancer Discov. 2022; 12(10):2392-2413.
PMID: 35924979
PMC: 9547930.
DOI: 10.1158/2159-8290.CD-21-1146.
Leukemic Stem Cell: A Mini-Review on Clinical Perspectives.
Barreto I, DE Pinho Pessoa F, Machado C, da Costa Pantoja L, Ribeiro R, Lopes G
Front Oncol. 2022; 12:931050.
PMID: 35814466
PMC: 9270022.
DOI: 10.3389/fonc.2022.931050.
Exploring the Metabolic Landscape of AML: From Haematopoietic Stem Cells to Myeloblasts and Leukaemic Stem Cells.
Mesbahi Y, Trahair T, Lock R, Connerty P
Front Oncol. 2022; 12:807266.
PMID: 35223487
PMC: 8867093.
DOI: 10.3389/fonc.2022.807266.
Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase.
Rana S, Mallareddy J, Singh S, Boghean L, Natarajan A
Cancers (Basel). 2021; 13(21).
PMID: 34771669
PMC: 8583118.
DOI: 10.3390/cancers13215506.
c-FOS drives reversible basal to squamous cell carcinoma transition.
Kuonen F, Li N, Haensel D, Patel T, Gaddam S, Yerly L
Cell Rep. 2021; 37(1):109774.
PMID: 34610301
PMC: 8515919.
DOI: 10.1016/j.celrep.2021.109774.
Chronic interleukin-1 exposure triggers selection for Cebpa-knockout multipotent hematopoietic progenitors.
Higa K, Goodspeed A, Chavez J, De Dominici M, Danis E, Zaberezhnyy V
J Exp Med. 2021; 218(6).
PMID: 33914855
PMC: 8094119.
DOI: 10.1084/jem.20200560.
Silencing long non-coding RNA XIST suppresses drug resistance in acute myeloid leukemia through down-regulation of MYC by elevating microRNA-29a expression.
Wang C, Li L, Li M, Wang W, Liu Y, Wang S
Mol Med. 2020; 26(1):114.
PMID: 33228517
PMC: 7685636.
DOI: 10.1186/s10020-020-00229-4.
Zeb1 modulates hematopoietic stem cell fates required for suppressing acute myeloid leukemia.
Almotiri A, Alzahrani H, Menendez-Gonzalez J, Abdelfattah A, Alotaibi B, Saleh L
J Clin Invest. 2020; 131(1).
PMID: 33108352
PMC: 7773410.
DOI: 10.1172/JCI129115.
1-Cinnamoyltrichilinin from Causes Apoptosis through the p38 MAPK Pathway in HL-60 Human Leukemia Cells.
Jeong H, Park S, Kim S, Cho S, Jeong M, Kim S
Int J Mol Sci. 2020; 21(20).
PMID: 33053881
PMC: 7589825.
DOI: 10.3390/ijms21207506.
The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles.
Aasebo E, Berven F, Hovland R, Doskeland S, Bruserud O, Selheim F
Cancers (Basel). 2020; 12(6).
PMID: 32512867
PMC: 7352627.
DOI: 10.3390/cancers12061466.
The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia.
Annageldiyev C, Tan S, Thakur S, Dhanyamraju P, Ramisetti S, Bhadauria P
Front Oncol. 2020; 10:393.
PMID: 32296637
PMC: 7140985.
DOI: 10.3389/fonc.2020.00393.
Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia.
Aasebo E, Berven F, Bartaula-Brevik S, Stokowy T, Hovland R, Vaudel M
Cancers (Basel). 2020; 12(3).
PMID: 32192169
PMC: 7140113.
DOI: 10.3390/cancers12030709.
Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia.
Panuzzo C, Signorino E, Calabrese C, Ali M, Petiti J, Bracco E
J Clin Med. 2020; 9(3).
PMID: 32188030
PMC: 7141302.
DOI: 10.3390/jcm9030802.